Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Solid Tumor, Adult
Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants
N/A N=12 Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
Cervical · Ovarian · Lung
Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)
Phase 2 N=64 Study of Tremelimumab in Patients With Advanced Solid Tumors
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
N/A N=42 Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Phase 2 N=130 A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Tumors
Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
N/A N=70 Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
Sarcoma · Thoracic Cancer · Abdominal Cancer
Primary: Rate of Local Control — 29 Participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
N/A N=20 The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Renal Cancer · Tumor, Solid · Kidney Cancer
Primary: Primary Effectiveness: Technical Success — 100.0 percentage of tumors
Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
N/A N=30 Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
Metastatic Carcinoma
Primary: Number of Participants With SABR Successfully Delivered in One Fraction — 30 Participants
Phase 2 N=50 Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants
Phase 1 N=29 Dose Finding Study of BI 836880 in Patients With Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 720 Milligram
Phase 1 N=78 Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Neoplasms
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 4; 4; 4; 4 Participants
Phase 2 N=29 M6620 (VX-970) in Selected Solid Tumors
Solid Tumor · Leiomyosarcoma · Osteosarcoma
Primary: Changes in Phospho-Chk1 Levels in Biopsy Specimens — 156; 196; 89; 84 percent change
Phase 1 N=34 AZD1775 for Advanced Solid Tumors
Solid Tumors
Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants
Phase 1 N=14 A Study of IMC-TR1 in Participants With Advanced Solid Tumors
Neoplasms · Tumor
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 2; 0; 2 Participants
Phase 1 N=69 Monotherapy Dose Finding With BI 847325 in Solid Tumours
Neoplasms
Primary: Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study — 0; 0; 0; 0 Percentage of participants
Phase 1 N=110 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
Neoplasms
Primary: Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) — 0; 0; 0 Participants
N/A N=38 Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors
Lung Cancer
Primary: Disease Status — 84; 78; 55; 54 percentage of participants
Phase 2 N=29 BN Brachyury and Radiation in Chordoma
Chordoma
Primary: Objective Response Rate (ORR) — 7.7 percentage of subjects with OR
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 1 N=51 Japanese Phase 1 Trial of Sym004 in Solid Tumors
Solid Tumors
Primary: Number of Subjects With Dose Limiting Toxicities (DLTs) Determined in Part-A — 0; 0; 0; 0 subjects
Phase 2 N=72 PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Progressive Desmoids Tumors
Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…
Phase 2 N=1,131 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
Phase 1 N=23 A Study Of PF-04449913 Administered Alone In Select Solid Tumors
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 2 Participants
Phase 2 N=109 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors · Lung Cancer · Breast Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 — 4; 4; 10; 12 Participants